Neoadjuvant Therapy With Trastuzumab, Paclitaxel and Epirubicin for HER-2–Positive Operable Breast Cancer

TY - JOUR

T1 - Neoadjuvant Therapy With Trastuzumab, Paclitaxel and Epirubicin for HER-2–Positive Operable Breast Cancer

AU - Ahluwalia, Manmeet S.

AU - Daw, Hamed A.

N1 - We read with interest the article by Buzdar et al,1 published in the June 1, 2005, issue of the Journal of Clinical Oncology, and would like to comment on the content and conclusions of the article. The study evaluated the benefit of adding trastuzumab to chemotherapy in the neoadjuvant setting.

PY - 2005/10/20

Y1 - 2005/10/20

UR - https://ascopubs.org/doi/full/10.1200/JCO.2005.03.0213

U2 - 10.1200/JCO.2005.03.0213

DO - 10.1200/JCO.2005.03.0213

M3 - Article

VL - 23

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -